Genmab A/S Sponsored ADR $GMAB Shares Purchased by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Genmab A/S by 111.5% during the 1st quarter, now owning over 1 million shares valued at approximately $21 million.
• Several other institutional investors, including Two Sigma Advisers LP and Marshall Wace LLP, have also boosted their holdings in Genmab A/S, indicating increasing interest in the company.
• Genmab A/S received multiple upgrades from analysts, with target prices raised and many ratings shifting to "buy," reflecting a general bullish sentiment on the stock.

Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 111.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,080,129 shares of the company's stock after purchasing an additional 569,345 shares during the period. Russell Investments Group Ltd. owned 0.17% of Genmab A/S worth $21,149,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in GMAB. Headlands Technologies LLC boosted its position in Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after purchasing an additional 1,464 shares during the period. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genmab A/S in the 4th quarter worth $60,000. Advisors Preferred LLC acquired a new position in Genmab A/S in the 1st quarter worth $84,000. Finally, Aquatic Capital Management LLC acquired a new position in Genmab A/S in the 4th quarter worth $114,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on GMAB. HC Wainwright boosted their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, August 15th. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Finally, Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.60.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded up $0.2080 during trading on Friday, reaching $24.6280. The company had a trading volume of 555,165 shares, compared to its average volume of 1,434,768. The company has a market cap of $15.80 billion, a price-to-earnings ratio of 12.37, a price-to-earnings-growth ratio of 6.98 and a beta of 0.95. The firm's fifty day moving average is $21.90 and its 200-day moving average is $21.04. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $27.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.